(Q36863124)

16 August 2017

1 reference

title

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management (English)

1 reference

16 August 2017

Jean-Michel Pawlotsky

6

object named as

Jean-Michel Pawlotsky

0 references

Yun-Fan Liaw

7

0 references

author name string

Anna S Lok

1

1 reference

16 August 2017

Fabien Zoulim

2

1 reference

16 August 2017

Stephen Locarnini

3

1 reference

16 August 2017

Angeline Bartholomeusz

4

1 reference

16 August 2017

Marc G Ghany

5

1 reference

16 August 2017

Masashi Mizokami

8

1 reference

16 August 2017

Carla Kuiken

9

1 reference

16 August 2017

Hepatitis B Virus Drug Resistance Working Group

10

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

46

1 reference

16 August 2017

254-265

1 reference

16 August 2017

1

1 reference

A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.

16 August 2017

1 reference

Management of hepatitis B: summary of a clinical research workshop

21 January 2018

1 reference

7 January 2021

Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity

1 reference

7 January 2021

Variant of hepatitis B virus with primary resistance to adefovir

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

7 January 2021

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

7 January 2021

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

7 January 2021

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

1 reference

7 January 2021

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

7 January 2021

Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors

1 reference

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

7 January 2021

Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments

1 reference

7 January 2021

Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine

1 reference

7 January 2021

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

1 reference

7 January 2021

Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.

1 reference

7 January 2021

European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes

1 reference

7 January 2021

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

1 reference

7 January 2021

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis

1 reference

7 January 2021

In vitro models for studying hepatitis B virus drug resistance

1 reference

7 January 2021

Generation of replication-competent hepatitis B virus nucleocapsids in insect cells.

1 reference

7 January 2021

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

1 reference

7 January 2021

In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

1 reference

7 January 2021

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

1 reference

7 January 2021

Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

1 reference

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

7 January 2021

Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.

1 reference

7 January 2021

The key lesson of family planning programmes for HIV/AIDS control

1 reference

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

7 January 2021

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

7 January 2021

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

1 reference

7 January 2021

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

7 January 2021

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

7 January 2021

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

1 reference

7 January 2021

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

1 reference

7 January 2021

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

1 reference

7 January 2021

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

1 reference

7 January 2021

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

1 reference

7 January 2021

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

1 reference

7 January 2021

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

7 January 2021

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

1 reference

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

7 January 2021

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

7 January 2021

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.

1 reference

7 January 2021

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

1 reference

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus

1 reference

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

7 January 2021

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

1 reference

7 January 2021

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21698

1 reference

16 August 2017

1 reference